Bicycle Therapeutics director Charles Swanton steps down from board
Bicycle Therapeutics plc disclosed that Charles Swanton left his board seat and advisory role on August 18, 2026, citing personal reasons.
Bicycle Therapeutics plc filed an 8-K reporting that Charles Swanton resigned as a Class II director of the company's Board of Directors, along with stepping down from Board committees and the company's Clinical Advisory Board, with the resignation taking effect immediately on August 18, 2026.1
The filing specified the reason behind the departure, stating that Dr. Swanton's resignation stemmed from personal reasons and did not involve any disagreement with the company over its operations, policies, or practices.1
The 8-K was signed on August 20, 2026 by Travis Thompson, identified as the company's Chief Financial Officer. Bicycle Therapeutics is registered in England and Wales, with its principal offices located in Cambridge, United Kingdom. The company's American Depositary Shares trade on The Nasdaq Stock Market under the ticker BCYC.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.